Obstetrix Medical Group
17
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
35.3%
6 terminated/withdrawn out of 17 trials
57.1%
-29.4% vs industry average
18%
3 trials in Phase 3/4
75%
6 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Evaluation of MHP 3.0 in Two Clinical Settings
Role: collaborator
National Prevalence and Impact of Noninvasive Prenatal Testing
Role: lead
Neonatal Outcome by Reason for Delivery
Role: lead
Optimal Management of Vasa Previa Study - A Retrospective Study
Role: lead
Vaginal Pessary Versus Expectant Management for Placenta Previa
Role: collaborator
Non-Invasive Screening for Fetal Aneuploidy
Role: collaborator
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
Role: lead
Maternal Uterine Artery Doppler Study
Role: lead
17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
Role: lead
A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
Role: lead
Cerclage for Prevention on Preterm Birth in Women With Placenta Previa
Role: lead
fFN & E3 in the Prediction of PTB in Women With Twin Pregnancies Receiving 17OHP or Placebo
Role: lead
Vaginal Progesterone in Twins With Short Cervix
Role: lead
Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR
Role: lead
Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)
Role: lead
Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes
Role: collaborator
Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes
Role: collaborator
All 17 trials loaded